First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

Inclusion Criteria: 1. Male or female participants aged ≥18 years. 2. Histologically or cytologically confirmed: 1. EGFR-mutated non-small cell lung cancer (NSCLC) with or without brain metastases previously treated with an EGFR inhibitor; or 2. IDH-mutated WHO Grade 3/4 recurrent glioma; or 3. Adenoid cystic carcinoma (ACC) with recurrent, metastatic, or advanced incurable disease. 3. At least one measurable lesion according to RECIST v1.1 and/or RANO criteria, as applicable. 4. ECOG performance status ≤2. 5. Adequate hematologic, hepatic, renal, and coagulation function. 6. Resolution of clinically significant toxicities from prior therapy to Grade 0 or 1, except permitted residual toxicities. 7. Life expectancy of at least 3 months. 8. Able to swallow oral medication. 9. Availability of tumor tissue and/or liquid biopsy suitable for next-generation sequencing. 10. Willing to use highly effective contraception during study participation and for at least 3 months after the last dose of study treatment. 11. Able and willing to provide written informed consent. Exclusion Criteria: 1. Systemic anticancer therapy or investigational therapy within 2 weeks or 5 half-lives prior to study treatment. 2. Major surgery within 21 days before study treatment. 3. Radiotherapy within 4 weeks for brain metastases or within 2 weeks for other disease sites. 4. Significant uncontrolled cardiovascular, metabolic, psychiatric, or other serious medical conditions. 5. QTcF \>450 msec in males or \>470 msec in females. 6. History of optic neuritis or optic neuropathy. 7. Active HIV infection or active hepatitis B or C infection. 8. Active infection requiring systemic antibiotic therapy. 9. Use of strong CYP3A inhibitors or inducers within protocol-specified washout periods. 10. Gastrointestinal conditions that may significantly affect drug absorption. 11. Pregnancy or breastfeeding. 12. Participation in another interventional clinical study. 13. Previous treatment with JBI-778. 14. Any condition that, in the opinion of the investigator, would place the participant at unacceptable risk or interfere with study participation.